During Wednesday’s Current trade, Shares of Energy Focus Inc(NASDAQ:EFOI), gain 6.58% to $28.40.
Energy Focus Inc (NASDAQ:EFOI) declared financial results for the second quarter ended June 30, 2015.
Financial Highlights:
- Record net sales of $16.6 million represents 148.1 percent in year-over-year growth and 26.4 percent sequential growth from the first quarter of 2015.
- Gross margin of 45.9 percent represents 13.4 percentage points of improvement year-over-year, and is 4.8 percentage points higher than the first quarter of 2015.
- Operating income of $3.1 million represents a $3.6 million year-over-year enhance from an operating loss of $562 thousand in the second quarter of 2014, and a $1.8 million enhance from the first quarter of 2015.
- Net income of $2.1 million, or $0.21 per share, represents a $2.7 million year-over-year enhance from the preceding year’s second quarter loss, and a $1.0 million enhance from the first quarter of 2015.
Energy Focus, Inc. designs, develops, manufactures, markets, and installs energy-efficient lighting systems and solutions in the United States and internationally. It operates in two segments, Products and Solutions. The company offers commercial, industrial, government, and military and maritime energy-efficient light-emitting diode (LED) lighting offerings, counting LED luminares and fixtures to serve the United States Navy; tubular LED replacements for linear fluorescent lamps; LED luminares and fixtures; LED docklights; tubular LED parking garage luminares and fixtures; LED cold storage globe luminares; and LED retrofit kits for high-intensity discharge applications.
Shares of Sanofi SA (ADR) (NYSE:SNY), inclined 0.50% to $50.26, during its current trading session.
Sanofi Pasteur, the vaccines division of Sanofi, declared that Vaccine published positive results from a new analysis of data from a large-scale, multi-center efficacy trial. In this new analysis, researchers observed significantly fewer serious cardio-respiratory events possibly related to influenza (“the flu”) in study participants 65 years of age and older who received a higher-dose split-virus inactivated influenza vaccine (IIV-HD) contrast to a standard-dose split-virus inactivated influenza vaccine (IIV-SD).
In the efficacy trial, a total of 31,989 adults 65 years of age and older were randomly assigned in a 1:1 ratio to receive either IIV-HD (Fluzone® High-Dose vaccine, Sanofi Pasteur, Swiftwater, PA) or IIV-SD (Fluzone vaccine, Sanofi Pasteur) and followed for six to eight months post-vaccination for the occurrence of influenza and serious events, counting events leading to death or hospitalization (or its prolongation), or events considered life-threatening or medically important, or resulting in disability. For the supplementary analysis stated in Vaccine, cardio-respiratory events were grouped into seven categories: pneumonia, asthma, chronic obstructive pulmonary disease (COPD) or bronchial events, influenza (laboratory-confirmed influenza diagnosed outside of normal study procedures), other respiratory events, coronary artery events, congestive heart failure, and cerebrovascular events.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Chico’s FAS, Inc. (NYSE:CHS), during its Wednesday’s current trading session gained 0.06% to $15.43.
Chico’s FAS, Inc. (CHS) declared its financial results for the fiscal 2015 second quarter and twenty-six weeks ended August 1, 2015, and a plan (the “Plan”) to sell the Boston Proper direct-to-consumer (“DTC”) business and close its existing stores.
For the thirteen weeks ended August 1, 2015 (“the second quarter”), the Company stated adjusted net income of $35.5 million contrast to net income of $30.1 million for the thirteen weeks ended August 2, 2014, and second quarter 2015 adjusted earnings per diluted share of $0.25 contrast to earnings per diluted share of $0.20 in last year’s second quarter. The second quarter adjusted results exclude net charges of $0.23 per diluted share in 2015 related to the Plan to exit Boston Proper and restructuring and planned charges (the “Net Charges”), as presented in the accompanying GAAP to Non-GAAP Reconciliation. Counting the impact of the Net Charges, the Company stated second quarter 2015 net income of $2.1 million, or $0.02 per diluted share.
Chico’s FAS, Inc. operates as an omni-channel specialty retailer of women’s private branded, casual-to-dressy clothing, intimates, complementary accessories, and other non-clothing items. The company’s portfolio of brands comprises of Chico’s, White House|Black Market (WH|BM), Soma Intimates (Soma), and Boston Proper. The Chico’s brand sells private branded clothing; and accessories, such as handbags, belts, scarves, earrings, necklaces, and bracelets focusing on women of age 40 and over.
Finally, Northrop Grumman Corporation (NYSE:NOC), gained 0.24%, to $168.41.
The board of directors of Northrop Grumman Corporation (NOC) declared a quarterly dividend of $0.80 per share on Northrop Grumman common stock, payable Sept. 16, 2015, to shareholders of record as of the close of business Aug. 31, 2015.
Northrop Grumman Corporation, a security company, provides systems, products, and solutions in aerospace, electronics, information systems, and technical service areas to government and commercial customers worldwide. The company’s Aerospace Systems segment designs, develops, integrates, and produces manned aircraft, unmanned systems, spacecraft, high-energy laser systems, microelectronics, and other systems and subsystems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
